Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tezepelumab in severe chronic rhinosinusitis with nasal polyps
2020-003062-39Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Tezepelumab with Placebo (2 arms). Primary endpoints: Change from baseline in total Nasal Polyp Score at Week 52 and Change from baseline in bi-weekly mean nasal congestion score. Started Oct 2020; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2020-003062-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003062-39.